Entering text into the input field will update the search result below

FDA accepts Trovagene's IND application for AML candidate PCM-075; shares ahead 3%

Jul. 27, 2017 11:54 AM ETCardiff Oncology, Inc. (CRDF) StockBy: Douglas W. House, SA News Editor6 Comments
  • Nano cap Trovagene (TROV +2.9%) perks up on modestly higher volume on the news that the FDA has accepted its Investigational New Drug (IND) application seeking authorization to initiate clinical studies assessing PLK1 inhibitor PCM-075 for the treatment of acute myeloid leukemia (AML).
  • First up will be a Phase 1b/2 open-label trial, first to identify the optimum dose and then to assess efficacy.

Recommended For You

About CRDF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CRDF--
Cardiff Oncology, Inc.